A Test to Predict the Hemolytic Potential of Drugs in G6PD Deficiency

Walter Reed Army Institute of Research (WRAIR)14 enrolled

Overview

This study will evaluate a new and safe testing method for identifying medicines that can cause problems in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals. We are looking for volunteers with G6PD deficiency who would be willing to donate blood samples.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

PREVENTION

Masking

NONE

Enrollment

Conditions

Glucosephosphate Dehydrogenase Deficiency Favism

Interventions

PrimaquineDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion: * Normal clinical evaluation * Willing and able to make all scheduled visits Exclusion: * pregnant or planning pregnancy * Have taken any anti-malarial medication in past month * Positive blood tests for HIV and specific types of hepatitis * Allergic to primaquine

Locations (1)

Walter Reed Army Institute of Research

Silver Spring, Maryland, United States

Outcomes

Primary Outcomes

Difference in degree of hemolysis of G6PD(-) red blood cells in treated vs untreated matched samples.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.